Core Viewpoint - Repligen Corporation will report its second quarter 2025 financial results on July 29, 2025, and will host a conference call to discuss these results and business updates [1] Group 1: Financial Reporting - The financial results for the three- and six-month periods ended June 30, 2025, will be discussed during the conference call [1] - A press release will be issued before the market opens on the same day [1] Group 2: Conference Call Details - The conference call can be accessed by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers, with no passcode required [2] - A webcast will also be available via the Investor Relations section of the Company's website, and both the call and webcast will be archived for later access [2] Group 3: Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies for the manufacturing of biological drugs [3] - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - The corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key locations in Europe [3]

Investor Presentation May 2025 1 January 14, 2025 Safe Harbor / Non-GAAP financial measures This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements in this presentation which are not strictly historical statements including, without limitation, express or implied statements or guidance regarding Repligen's financial results for full year 2025, future financial performance and other statements identified by words like "estimated," "anticipated," "gu ...

Core Insights - Repligen Corporation has published its 2024 Corporate Sustainability Report themed "Perspectives on Progress," highlighting advancements in sustainability across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Partnerships & Pathways [1][2] - The report includes disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and key reporting frameworks such as the Global Reporting Initiative (GRI) Standards and Sustainability Accounting Standards Board (SASB) [1] Sustainability Highlights - The company transitioned to 100% renewable electricity across all 19 manufacturing sites, representing 100% of total global consumption [6] - Waste generation was reduced by 25%, and total waste intensity decreased by 32% on a normalized-to-revenue basis from 2023 to 2024 [6] - The global Scope 3 emissions inventory was expanded to cover all material emissions categories, increasing from 9 to 11 out of 15 compared to 2023 [6] - Repligen completed the UNGC Network USA Business and Human Rights Accelerator program, integrating the learnings into its corporate sustainability strategy [6] - A new customer-focused Repligen Training and Innovation Center (RTIC) was opened in Waltham, MA [6]

Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems that enhance the manufacturing efficiency of biological drugs [3] - The company primarily serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide [3] - Key focus areas include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] Upcoming Event - Repligen will participate in the William Blair 45th Annual Growth Stock Conference from June 3 to June 5 in Chicago [1] - Olivier Loeillot, President and CEO, is scheduled to present a company overview on June 3 at 1:20 p.m. CT [1] - A live webcast of the presentation will be available on Repligen's Investor Relations website and will be accessible for replay for a limited time after the event [2]

Summary of Technova Conference Call Company Overview - **Company**: Technova - **Industry**: Life Sciences, specifically reagents for biotech, pharma, and diagnostics - **Founded**: 1996 by a scientist from Genentech - **Public Offering**: Took the company public in February 2021 Key Points and Arguments - **Market Position**: Technova is a leading provider of reagents for the life science community, serving over 3,000 customers in the U.S. [3][4] - **Growth Trajectory**: The company has historically grown at 12% since February 2009 and aims for a top-line growth of 20-25% due to clinical programs in the pipeline [4][47] - **Revenue Potential**: Technova is positioned to scale its business to $200-250 million in revenue without significant additional capital expenditures (CapEx) [4][41] - **Gross Margin**: 70% of every additional dollar in revenue contributes to the bottom line, indicating strong profitability potential [5][56] - **Customer Retention**: The company boasts a 95% retention rate of its customer base year on year, making it difficult for customers to switch suppliers [53] Product Offerings - **Product Categories**: - Catalog products (60% of business) for general R&D and academic use [16] - Custom products (35% of business), with 25% of that being biopharma-related [18] - **Growth in Custom Products**: Custom biopharma products grew by 40% last year, indicating strong demand [18] - **Speed of Delivery**: Technova can deliver research-use products in 2-3 weeks and custom GMP products in 4-8 weeks, significantly faster than competitors who may take 4-8 months [28][29] Competitive Advantage - **Customization and Quality**: Technova focuses on providing high-quality, customized reagents quickly, which is a gap in the market compared to larger players [10][19] - **Modular Manufacturing**: The company employs a modular manufacturing approach, allowing for flexibility in production sizes and formulations [25][27] - **Customer Service**: High levels of customer service and support, reflected in a net promoter score in the seventies [22] Financial Outlook - **Capital Position**: Technova had $26 million in cash at the end of Q1 and an untapped revolving line of credit, providing a solid financial foundation [61] - **Path to Profitability**: Adjusted EBITDA breakeven is expected at $50-55 million in revenue, with cash flow positive anticipated shortly thereafter [62] Industry Context - **Biotech Environment**: The company is navigating a challenging biotech funding environment but continues to gain clinical customers, projecting a 15% growth in this segment by 2025 [52] - **Regulatory Impact**: Technova feels insulated from tariff impacts due to its U.S.-based manufacturing and limited reliance on foreign raw materials [49][50] Future Strategies - **Partnerships and Collaborations**: Technova is looking to expand partnerships, such as the recent collaboration with Pluristics for cryopreservation media, to enhance its product offerings [45][58] - **Focus on Emerging Therapies**: The company aims to support the growing complexity in bioprocessing for therapies like cell and gene therapy, which require more customized solutions [36][39] Conclusion - **Long-term Growth**: Technova is positioned for sustainable growth with a strong foundational business, significant investments already made, and a clear strategy to scale operations without the need for further major investments [47][48]

Core Insights - Scientific Industries, Inc. reported a 5% revenue growth in its Benchtop Lab Equipment Operations for Q1 2025, driven by the Genie and Torbal Divisions, with a notable increase in US-based customers [4][5][6] - Overall revenue for the first quarter decreased by 3% due to a significant decline in international sales, which fell by 33% [4][6] - The company secured $1.5 million in equity financing and reported a decreased net loss of $1.78 million, improving from a loss of $2.05 million in the same period last year [5][9] Financial Overview - Net revenues for Q1 2025 totaled $2.41 million, down from $2.48 million in Q1 2024, primarily due to a $182,600 decrease in Bioprocessing Systems Operations revenues [6][17] - Benchtop Laboratory Equipment revenues increased to $2.3 million, a 5% rise compared to $2.2 million in the prior year [5][17] - Bioprocessing Systems Operations revenues decreased by 58% to $133,500 from $316,100 in the previous year [5][17] Profitability Metrics - Gross profit for Q1 2025 was $1.02 million, slightly down from $1.04 million in Q1 2024, with a gross margin of 42.2%, up from 41.9% [7][17] - Operating expenses decreased by 9.7% to $2.83 million, attributed to cost-cutting measures implemented in fiscal 2024 [8][17] - The company reported a basic and diluted loss per share of $0.16, an improvement from $0.20 in the same quarter last year [9][17] Strategic Developments - The company is planning to scale its DOTS platform with the launch of a new optical pH sensor and high-performance liquid injection system in the second half of 2025 [4] - A peer-reviewed publication validated the DOTS Multiparameter platform, confirming its sensitivity and reliability compared to industry standards [4][5]

Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems for manufacturing biological drugs [3] - The company operates primarily in areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - Repligen's headquarters is located in Waltham, Massachusetts, with manufacturing sites in the U.S. and additional locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3] Upcoming Events - Repligen will participate in the RBC Capital Markets' 2025 Global Healthcare Conference in New York on May 20-21, where CFO Jason K. Garland will engage in an analyst-led discussion and one-on-one meetings with investors [4] - The company will also attend Craig-Hallum's 22nd Annual Institutional Investor Conference in Minneapolis on May 28, with CFO Jason K. Garland participating in one-on-one meetings [4] Investor Relations - A live webcast of the RBC conference presentation will be available on Repligen's Investor Relations website, with a replay accessible for a limited time after the event [2]

Core Insights - Repligen Corporation reported a strong start to 2025 with revenues of $169 million, reflecting a 10% year-over-year increase and 14% organic non-COVID growth, alongside a significant expansion in adjusted operating margins [2][6][8] - The company experienced nearly 20% growth in total orders, with all four business franchises achieving double-digit growth, indicating robust business momentum [2][6] - Repligen has updated its financial guidance for the full year 2025, projecting total reported revenue between $695 million and $720 million, with organic growth expectations of 9.5% to 13.5% [10][11] Financial Performance - Q1 2025 financial highlights include: - Revenue of $169 million, a 10% increase from $153 million in Q1 2024 [6][8] - Adjusted operating income rose by 72% year-over-year [6] - GAAP net income was $6 million, compared to $3 million in the prior year [8] - Adjusted earnings per share increased to $0.39 from $0.30 [8] Margin Summary - Gross margin improved to 53.6% in Q1 2025 from 50.1% in Q1 2024 [5][28] - Adjusted operating margin increased to 13.8% from 8.9% year-over-year [5][23] - Adjusted EBITDA margin rose to 19.3% compared to 14.4% in the previous year [5][26] Business Highlights - Revenues from biopharma and consumables grew over 20% year-over-year, reaching record levels excluding COVID-related sales [7] - The acquisition of 908 Devices' bioprocessing portfolio was completed, enhancing Repligen's process analytical technology offerings [7] - The launch of the CTech™ SoloVPE® Plus System introduced next-generation UV-based Variable Pathlength Technology, emphasizing accuracy and ease of use [7] Cash Position - As of March 31, 2025, cash and cash equivalents stood at $697 million, down from $757 million at the end of 2024 [9] Updated Financial Guidance - The updated guidance for FY 2025 includes: - Total reported revenue of $695 million to $720 million [11] - Adjusted net income projected between $92 million and $97 million [11][31] - Adjusted earnings per share expected to be between $1.63 and $1.72 [11][33]

Core Points - Repligen Corporation will report its first quarter 2025 financial results on April 29, 2025, with a conference call scheduled for 8:30 a.m. ET to discuss business updates and financial results for the period ending March 31, 2025 [1] Group 1: Financial Reporting - The company will issue a press release before the market opens on the reporting date [1] - A conference call will be accessible for domestic and international callers, with no passcode required for the live call [2] Group 2: Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies for manufacturing biological drugs [3] - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - The corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key sites in Europe [3]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $1.69 billion, reflecting a low single-digit organic growth, marking a significant milestone in the recovery process [7][18] - Adjusted EBITDA margin expanded to 18.2%, the highest level in over a year, driven by an improved mix and benefits from a multi-year cost transformation initiative [7][19] - Adjusted earnings per share increased to $0.27 in Q4, up 4% sequentially and 8% year over year [7][20] - For the full year, reported revenue was $6.78 billion, representing a 2% organic revenue decline compared to the previous year [22][23] Business Line Data and Key Metrics Changes - The Laboratory Solutions segment generated $1.13 billion in revenue for Q4, a 1% decline on an organic basis, while full-year revenue was $4.61 billion, down 2% [24][26] - The Bioscience Production segment achieved Q4 revenue of $561 million, with organic growth of 4%, driven by high single-digit growth in bioprocessing [27][29] - Adjusted operating income for Laboratory Solutions was $147 million in Q4, with a margin of 13.1%, while for Bioscience Production, it was $149 million with a margin of 26.6% [26][27] Market Data and Key Metrics Changes - The academic end market remains strong, with large pharma customers increasing investments in preclinical activities, supporting growth in 2025 [9][10] - The company anticipates low single-digit organic growth in lab solutions and mid-single-digit growth in bioscience production for 2025 [29][30] Company Strategy and Development Direction - The company is focused on deleveraging, having paid down $1.3 billion of debt in 2024, reducing net leverage to 3.2 times [16][24] - A balanced, value-driven capital allocation approach is planned once the leverage target is achieved, with a focus on innovation-driven growth and margin expansion [16][30] - The introduction of new products and services, including digital tools and generative AI solutions, is part of the long-term growth strategy [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's momentum entering 2025, with expectations for organic growth, margin expansion, and double-digit EPS growth [39][40] - The company is monitoring the macro environment closely, particularly regarding potential policy changes from the new administration, but remains optimistic about funding for good science [66][67] Other Important Information - The company generated $768 million in free cash flow for the year, exceeding original guidance [23][21] - The clinical services divestiture is expected to have a 2% headwind on revenue, with additional impacts from foreign exchange [29][32] Q&A Session Summary Question: Order trends in bioprocessing and guidance assumptions - Management noted strong order intake in bioprocessing with no significant pull forward of orders, indicating a solid market foundation [42][45] Question: Clarification on margin guidance - Management explained the wide margin range reflects the fixed cost structure and potential for better conversion with higher sales [48][53] Question: Performance of the lab business in Q4 - Management acknowledged a muted seasonal ramp and macro uncertainties affecting lab performance, but highlighted resilience in the business model [58][61] Question: Policy risks and customer behavior changes - Management indicated limited direct exposure to NIH funding and remains confident in the overall business environment despite potential policy changes [66][67] Question: Impact of new distribution agreements - Management anticipates low single-digit growth for the lab business in 2025, with new agreements expected to contribute positively to growth [101][102]